Sechenov University has started the second phase of trials of Biocad’s drug for spondylitis deformans

The Center for Clinical Study of Medicines of Sechenov First Moscow State Medical University has launched the second phase of clinical trials of Biocad’s BCD-180, a drug designed to alleviate the condition of patients with spondylitis deformans. The first stage was successful, according to a report on the university’s website.

The first phase of the trial did not reveal any serious adverse reactions in the subjects. During the second phase, it is planned to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of the drug, including among people of Asian origin, since it is planned to have the product registered in China. The subjects of the trial are volunteers aged 18 to 45 years.

Ankylosing spondylitis (spondylitis deformans) is a chronic disease of the musculoskeletal system that affects young people and progresses rapidly, often leading to disability. Today it is incurable, as existing medications can only temporarily slow down its progression.

The BCD-180 is being tested not only in Russia, but also in Belarus, the trials being in accordance with Russian and international standards.

Source